Active	Status	Sponsor type	Region	Phase	Filter
8 Active 4 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
meplazumab / Jiangsu Pacific Meinuoke Biopharmaceutical, Air Force Medical University
NCT05679492: Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19	Withdrawn	3	1320	RoW	Meplazumab foe injection, Normal saline	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	COVID-19	09/23	12/23
NCT05813587: To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19	Completed	3	121	RoW	Meplazumab for injection, Normal saline	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	Post-COVID-19	09/23	10/23
NCT05679479: Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19	Completed	3	108	RoW	Meplazumab for injection, Normal saline	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	COVID-19	01/24	04/24
NCT05113784: the Safety and Efficacy of Meplazumab in Patients With COVID-19	Completed	2/3	150	RoW	Meplazumab for Injection, Sterile normal saline (0.9%)	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	Covid19	09/22	10/22
NCT04586153: Study to Assess the Effect of Meplazumab on COVID-19	Completed	2/3	174	RoW	Meplazumab for Injection, Sterile normal saline (0.9%)	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	COVID-19	12/22	12/22
NCT06040346: Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum	Active, not recruiting	2	60	RoW	Meplazumab for Injection	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	Malaria	08/25	10/25
REC-SAFECAD, NCT06572267: Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease	Recruiting	2	18	RoW	Mepolizumab low dose group, Mepolizumab middle dose group, Mepolizumab high dose group, Saline	Xijing Hospital	Coronary Artery Disease	09/25	03/26
NCT04327310: Clinical Study of Meplazumab to Treat With Malaria	Withdrawn	1	112	NA	Meplazumab for Injection, Meplazumab, Sterile normal saline (0.9%)	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	Malaria (Plasmodium Falciparum)	12/23	03/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
meplazumab / Jiangsu Pacific Meinuoke Biopharmaceutical, Air Force Medical University
NCT05679492: Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19	Withdrawn	3	1320	RoW	Meplazumab foe injection, Normal saline	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	COVID-19	09/23	12/23
NCT05813587: To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19	Completed	3	121	RoW	Meplazumab for injection, Normal saline	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	Post-COVID-19	09/23	10/23
NCT05679479: Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19	Completed	3	108	RoW	Meplazumab for injection, Normal saline	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	COVID-19	01/24	04/24
NCT05113784: the Safety and Efficacy of Meplazumab in Patients With COVID-19	Completed	2/3	150	RoW	Meplazumab for Injection, Sterile normal saline (0.9%)	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	Covid19	09/22	10/22
NCT04586153: Study to Assess the Effect of Meplazumab on COVID-19	Completed	2/3	174	RoW	Meplazumab for Injection, Sterile normal saline (0.9%)	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	COVID-19	12/22	12/22
NCT06040346: Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum	Active, not recruiting	2	60	RoW	Meplazumab for Injection	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	Malaria	08/25	10/25
REC-SAFECAD, NCT06572267: Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease	Recruiting	2	18	RoW	Mepolizumab low dose group, Mepolizumab middle dose group, Mepolizumab high dose group, Saline	Xijing Hospital	Coronary Artery Disease	09/25	03/26
NCT04327310: Clinical Study of Meplazumab to Treat With Malaria	Withdrawn	1	112	NA	Meplazumab for Injection, Meplazumab, Sterile normal saline (0.9%)	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	Malaria (Plasmodium Falciparum)	12/23	03/24